We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Methylation Profiling for Determining Gene Activity

By Biotechdaily staff writers
Posted on 01 Sep 2004
Researchers working with the plant Arabidopsis have used a powerful new microarray-based methylation profiling technology to study the role of epigenetic information in determining gene activity.

In their study, the investigators at Cold Spring Harbor Laboratory (NY, USA) utilized the MethylScope technology of Orion Genomics (Saint Louis, MO, USA). More...
MethylScope employs a microarray analysis technique to assess to what extent genes in a genome are methylated. The technology relies on proprietary methods to divide genomic DNA into two fractions: methylated and unmethylated.

Each fraction is labeled with a different color of fluorescent dye (e.g., unmethylated DNA is green and methylated DNA is red and is then hybridized to a microarray. If an array feature corresponding to a single gene in the genome glows red, then that gene was methylated in the tissue from which the DNA was prepared. If, however, an array feature glows green, then that gene was unmethylated. Observing the red-green ratio for each feature on an array allows investigators to quantitatively determine the degree to which a gene may be methylated.


The investigators reported in the August 6, 2004, issue of Nature that the DNA sequences at the sites of transposon activity correspond to small interfering RNAs (siRNAs). They also showed that transposable elements could regulate genes epigenetically, but only when inserted within or very close to them.

"Our research concerns the mechanism by which methylated DNA and other epigenetic information determines gene activity,” said senior author Dr. Rob Martienssen, a professor at Cold Spring Harbor Laboratory and co-founder of Orion Genomics. "Because of this ‘second code,' epigenetic changes are emerging as important defects in childhood diseases as well as in cancer. The profiling technology described in this paper will help to uncover these epigenetic defects, providing biomarkers and leads for potential therapy.”





Related Links:
Cold Springs Harbor Laboratory
Orion Genomics

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.